| Karen Massey |
Ms. Karen Massey is a Chief Operating Officer at argenx SE. Ms. Massey was previously employed as a Senior Vice President-Product Development by Genentech, Inc. and a Principal by Pfizer Inc. She received her undergraduate degree from The University of Sydney and an MBA from The Leonard N Stern School of Business. |
| Peter Ulrichts |
Dr. Peter Ulrichts is a Chief Scientific Officer at argenx SE. Dr. Ulrichts was previously employed as a Principal by Fédération catholique romaine neuchâteloise. He received his undergraduate degree from Katholieke Universiteit Leuven, a graduate degree from Ghent University and a doctorate degree from Ghent University. |
| Luc Truyen |
Dr. Luc Truyen is a Chief Medical Officer at argenx SE. Dr. Truyen was previously employed as a Chief Marketing Officer & Head-R&D by Janssen Alzheimer Immunotherapy and a Head-Research & Development by Johnson & Johnson Pharmaceutical Group. He received his doctorate degree from the University of Antwerp. |
| Karl Gubitz |
Mr. Karl Gubitz is a Chief Financial Officer at argenx SE. Mr. Gubitz was previously employed as a Vice President-Finance by Pfizer Inc. He received his undergraduate degree from the University of Pretoria, an undergraduate degree from the University of South Africa and an MBA from Henley Management College. |
| Tim van Hauwermeiren |
Mr. Tim van Hauwermeiren is an Independent Non-Executive Director at iTeos Therapeutics SA, an Independent Director at iTeos Therapeutics, Inc., a Chairman at Aelin Therapeutics NV and a Chief Executive Officer & Executive Director at argenx SE. He is on the Board of Directors at iTeos Therapeutics SA, iTeos Therapeutics, Inc. and argenx SE. Mr. van Hauwermeiren was previously employed as an Independent Director by Rayzebio, Inc., a Senior Manager-Business Development by Ablynx NV, and a Group Head by Procter & Gamble Co. He received his undergraduate degree from Ghent University, a graduate degree from Ghent University and an MBA from Vlerick Leuven Gent Management School. |
| Peter K. M. Verhaeghe |
Peter K. M. Verhaeghe is currently the Chairman at Haretis SA since 2011, the Non-Executive Chairman at argenx SE since 2008, the Non-Executive Director at miDIAGNOSTICS NV since 2020, and a Partner at Vermulst Verhaeghe & Graafsma. He previously served as the Managing Partner at VVGB Advocaten since 1999. Dr. Verhaeghe has also held various director positions at PharmaNeuroBoost NV, Galapagos NV, Fujirebio Europe NV, Merisant Co., Tibotec Virco NV, Movetis NV, Biocartis SA, Tools & Dies Engineering NV, KBC Private Equity Fund Biotech NV, Czechpak Manufacturing Sro, Katholieke Universiteit Leuven, Merisant France SAS, and Merisant Company 2 SARL. He obtained a graduate degree from Katholieke Universiteit Leuven in 1981 and a graduate degree from Harvard Law School in 1984. |
| Filip Borgions |
Dr. Filip Borgions is a Global Head-Technical Operations at argenx SE. Dr. Borgions was previously employed as a Principal by Thrombogenics, Inc. He received his undergraduate degree from Katholieke Universiteit Leuven and a doctorate degree from Katholieke Universiteit Leuven. |
